More recently, RIPK3 was shown to contribute immunogenic cell death that leads to anti‐tumor immune responses through promoting cross‐priming of CD8+ T cell vaccination responses in tumor microenvironment.[12] Therefore, understanding the mechanisms by which RIPK3 contributes to the anti‐tumor response could be a promising target for immunotherapy in many cancer diseases. Here, CD8A is linked to neoplasm.